GlassScriptPhysician profile
Tej-Preet Singh
NPI 1194798280
$14,185.75
in general payments reported to CMS, 2019-2025
75 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,161 · 2020: $1,693 · 2021: $2,656 · 2022: $3,018 · 2023: $2,080 · 2024: $1,237 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,040 · Entertainment: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,040.28 |
| Entertainment | $616.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,589.11 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Keystone Dental INC. | $1,444.23 | 2021-2025 | |
| Ucb, INC. | $760.03 | 2019-2024 | Briviact, Rystiggo |
| Biogen, INC. | $720.96 | 2019-2025 | Vumerity, Plegridy |
| Eisai INC. | $708.74 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $543.53 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $539.21 | 2019-2023 | Ajovy |
| Lundbeck LLC | $505.56 | 2019-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $462.72 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $412.90 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Alexion Pharmaceuticals, INC. | $391.94 | 2019-2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $377.64 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $337.47 | 2019-2021 | |
| Allergan, INC. | $335.68 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $307.85 | 2019-2025 | Dysport |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tej-Preet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.